Ad hoc news

to the archive

Dermapharm Holding SE signs cooperation and delivery agreement with BioNTech SE

Grünwald, September 10, 2020 – Dermapharm Holding SE (WKN: A2GS5D, ISIN: DE000A2GS5D8) and BioNTech SE, Mainz, Germany, have agreed that their production subsidiaries will cooperate on producing a COVID-19 vaccine. The production capacities at Dermapharm will be available to the cooperation partners BioNTech SE and Pfizer Inc. already when production of the vaccine begins.

Contacts
Investor Relations &
Corporate Communications
Britta Hamberger
Phone: +49 (0)89 – 64186-233
Fax: +49 (0)89 – 64186-165
E-mail: ir@dermapharm.com

cometis AG
Claudius Krause
Phone: +49 (0)611 – 205855-28
Fax: +49 (0)611 – 205855-66
E-mail: ir@dermapharm.com

Michael Diegelmann

Newsletter subscription

Contact

+49 611 205 855 0

(Mon. - Fri. 09.00 - 18.00)

Answer Mon. - Fri.

within 24 hours

Newsletter subscription

Including a free extract of our bestseller book

Michael Diegelmann
Henryk_Deter

Newsletter subscription

Contact

+49 611 205 855 0

(Mon. – Fri. 09.00 – 18.00)

Answer Mon. – Fri.

within 24 hours

Newsletter subscription

Including a free extract of our bestseller book